Literature DB >> 2411049

Location of antigenic sites on the three-dimensional structure of the influenza N2 virus neuraminidase.

G M Air, M C Els, L E Brown, W G Laver, R G Webster.   

Abstract

Sequence analysis of the neuraminidase (NA) genes of influenza virus X-7(F1) and of 12 variants selected with monoclonal antibodies has been used to define in physical terms the antigenic structure of this NA, which was operationally established by R. G. Webster, L. E. Brown, and W. G. Laver (1984, Virology 135, 30-42). X-7(F1) is a reassortant virus containing the NA of the early Asian (H2N2) isolate A/RI/5+/57, and the results of antigenic and sequence analysis of X-7(F1) and of variants selected with monoclonal antibodies have been combined with a similar analysis of the A/Tokyo/3/67 NA (H2N2, M. R. Lentz, G. M. Air, W. G. Laver, and R. G. Webster (1984), Virology 135, 257-265) to obtain a model of antibody binding to N2 NAs. The selection process was biased, however, since only those monoclonal antibodies which inhibited NA activity could be used to select variants. Most of the changes in the variants selected with monoclonal antibodies occur in those parts of the polypeptide chain which encircle the enzyme active site pocket in the three-dimensional structure (P. M. Colman, J. N. Varghese, and W. G. Laver (1983), Nature (London) 303, 41-44). The results suggest that in general the antibody binds to a site on the NA which includes those amino acid side chains which are altered in monoclonal variants. There are, however, several aspects of the antigen-antibody interaction which are not easily explained, and which will probably only be fully elucidated by X-ray crystallographic analysis of NA-antibody complexes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2411049     DOI: 10.1016/0042-6822(85)90157-6

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  49 in total

1.  Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98).

Authors:  Upma Gulati; Chi-Ching Hwang; Lalitha Venkatramani; Shelly Gulati; Stephen J Stray; Janis T Lee; W Graeme Laver; Alexey Bochkarev; Adam Zlotnick; Gillian M Air
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  Three antibody molecules can bind simultaneously to each monomer of the tetramer of influenza virus neuraminidase and the trimer of influenza virus hemagglutinin.

Authors:  D C Jackson; B S Crabb; P Poumbourios; W R Tulip; W G Laver
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

3.  Epitope analysis for influenza vaccine design.

Authors:  Enrique T Muñoz; Michael W Deem
Journal:  Vaccine       Date:  2005-01-19       Impact factor: 3.641

4.  Mechanism of antigenic variation in an individual epitope on influenza virus N9 neuraminidase.

Authors:  G M Air; W G Laver; R G Webster
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

5.  Influenza virus neuraminidase contributes to secondary bacterial pneumonia.

Authors:  Ville T Peltola; K Gopal Murti; Jonathan A McCullers
Journal:  J Infect Dis       Date:  2005-06-08       Impact factor: 5.226

6.  Quantifying influenza vaccine efficacy and antigenic distance.

Authors:  Vishal Gupta; David J Earl; Michael W Deem
Journal:  Vaccine       Date:  2006-01-19       Impact factor: 3.641

7.  Antigenic and structural properties of the hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 3: sequence analysis of variants selected with monoclonal antibodies which inhibit infectivity, hemagglutination, and neuraminidase activities.

Authors:  K L van Wyke Coelingh; C C Winter; E D Jorgensen; B R Murphy
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

8.  Conserved epitopes on the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: nucleotide sequence analysis of variants selected with monoclonal antibodies.

Authors:  K J Coelingh; C C Winter; B R Murphy; J M Rice; P C Kimball; R A Olmsted; P L Collins
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

9.  Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140.

Authors:  S Bantia; A A Ghate; S L Ananth; Y S Babu; G M Air; G M Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

10.  Identification of amino acid changes that may have been critical for the genesis of A(H7N9) influenza viruses.

Authors:  Gabriele Neumann; Catherine A Macken; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.